AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34956230
Drug: G allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G allele of rs1049174
Trial: 34957480
Drug: Modified plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified plasmid for selection without antibiotic resistance
Trial: 34957654
Drug: Oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral semaglutide 3 mg once daily for 5 days, followed by 7 mg for 5 days
Trial: 34958928
Drug: Lazertinib 240
RxNorm normalized name: lazertinib 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib 240 mg
Trial: 34959982
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral vitamin D supplementation (100,000 IU 25-OH VD every 3 weeks from day 1 of cycle 1 to day 1 of cycle 5)
Trial: 34959982
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral vitamin D supplementation
Trial: 34961476
Drug: High hs-CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hs-CRP levels (> 3 mg/L)
Trial: 34961476
Drug: High hs-CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hs-CRP levels (> 3 mg/L) and hypoalbuminemia
Trial: 34961547
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg daily for 14 weeks)
Trial: 34961567
Drug: Optimized standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized standard of care (control) including billboards/posters, radio shows, healthcare worker training, one-stop adolescent and youth-friendly services, information/motivation walls, pill containers, and tools for HCW during clinical visits.
Trial: 34961659
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose rate brachytherapy or stereotactic body radiotherapy
Trial: 34961659
Drug: Single-fraction high
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-fraction high dose rate brachytherapy
Trial: 35857060
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment for T2DM
Trial: 34965890
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral selinexor with different standard chemotherapies
Trial: 34965951
Drug: Trabectedin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in STS cohort
Trial: 34965951
Drug: Trabectedin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in ovarian carcinoma cohort
Trial: 34966667
Drug: Home-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physical activity program during neoadjuvant chemotherapy (NACT) combining aerobic and strengthening exercises.
Trial: 34966798
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo or standard treatment not specified)
Trial: 34967751
Drug: Tablet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based cognitive battery (Adaptive Cognitive Evaluation [ACE])
Trial: 34967751
Drug: Tablet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based cognitive battery (ACE)
Trial: 34967916
Drug: Ixekizumab 80
RxNorm normalized name: ixekizumab 80 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixekizumab 80 mg Q2W from Week 12 to Week 20
Trial: 34968102
Drug: Specific instrumental
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific instrumental activities of daily living (IADL) training (one intervention)
Trial: 34968106
Drug: varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varenicline (1 mg/bid)
Trial: 34968106
Drug: varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varenicline (1 mg/bid) plus naltrexone (50 mg/day)
Trial: 34969664
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy for insomnia (CBT-I), 5 sessions, gold-standard treatment.
Trial: 34969664
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy for insomnia (CBT-I)
Trial: 34969665
Drug: Indigo naturalis
RxNorm normalized name: indigo
DrugBank: Indigo (DB16862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigo naturalis (IN) 500 mg/day or 1.5 g/day for 8 weeks
Trial: 34970744
Drug: Free epithelialized
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free epithelialized gingival/mucosal grafts (FEGs) used for KT augmentation
Trial: 34970774
Drug: Intravenous voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous voriconazole therapy
Trial: 34971971
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (Zol) in conjunction with radiation therapy (RT)
Trial: 34972609
Drug: Volume challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume challenge (200 ml saline in 20 s)
Trial: 34973077
Drug: Tofacitinib 5→10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5→10 mg BID (Dose-up)
Trial: 34973077
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg BID (Stay-on 5)
Trial: 34973077
Drug: Tofacitinib 10→5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10→5 mg BID (Dose-down)
Trial: 34973077
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg BID (Stay-on 10)
Trial: 34973601
Drug: Racemic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic ketamine treatment
Trial: 34974453
Drug: Homologous third
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous third dose of inactivated whole-virion vaccine
Trial: 34974510
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (2 mg) with a treat-and-extend regimen
Trial: 34975844
Drug: Allogeneic Vγ9Vδ2
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic Vγ9Vδ2 T-cell therapy adjunct with anti-TB drugs
Trial: 34976830
Drug: AdHER2 DC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdHER2 DC vaccine
Trial: 34977109
Drug: Oral Nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Nutritional Supplementation
Trial: 34977512
Drug: Fresh lemon
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL SPRAY [PH5B Disinfectant Fresh Lemon]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh lemon juice supplementation (60 mL twice daily)
Trial: 34977602
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of SARS-CoV-2 vaccines
Trial: 34977602
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of SARS-CoV-2 vaccines
Trial: 34977602
Drug: Healthy controls
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy controls receiving two doses of SARS-CoV-2 vaccines
Trial: 34977972
Drug: Erdafitinib 6-mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib 6-mg/day
Trial: 34977972
Drug: Erdafitinib 8-mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib 8-mg/day
Trial: 34977972
Drug: Erdafitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib (both doses)
Trial: 34978890
Drug: Monthly long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly long-acting cabotegravir + rilpivirine
Trial: 34978890
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dolutegravir/abacavir/lamivudine
Trial: 34978890
Drug: Long-acting therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting therapy
Trial: 34979020
Drug: Blinatumomab (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (up to 5 cycles, continuous infusion, cycle: 4 weeks on/2 weeks off)
Trial: 34979970
Drug: PDI drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDI drugs (e.g., Zolpidem, Zopiclone, Bromazepam, Tramadol, Pregabalin)
Trial: 34979970
Drug: PDI drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDI drugs
Trial: 34980038
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with three cycles of carboplatin and paclitaxel
Trial: 34980038
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose arm (chemoradiation to 70 Gy with concurrent cisplatin)
Trial: 34980176
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of an adenovirus targeting SNHG15
Trial: 34980208
Drug: Personalized daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized daily text messaging (SMS/MMS), posts on social media platforms, and online groups
Trial: 34980208
Drug: Personalized daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized daily text messaging (SMS/MMS), posts on social media platforms, online groups, and brief technology-mediated health coaching
Trial: 34980220
Drug: Intramuscular progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular progesterone 40 mg per day from D3 to 8 weeks of gestation if clinical pregnancy is achieved.
Trial: 34980224
Drug: Hydrocortisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (50 mg intravenous bolus every 6 hours) and fludrocortisone (50 μg once a day enterally) for 7 days or until discharge from the ICU
Trial: 34980502
Drug: SSTR2-targeted peptide-radionuclide
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSTR2-targeted peptide-radionuclide receptor therapy (PRRT)
Trial: 34980541
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab (arms B&C)
Trial: 34980597
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg every 2 weeks + cabozantinib 40 mg every day
Trial: 34980597
Drug: Nivolumab 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 480 mg every 4 weeks + cabozantinib 40 mg every day
Trial: 34980633
Drug: Point-of-care C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care C reactive protein (POC CRP) testing, prescription guidance, and safety-netting advice.
Trial: 34980909
Drug: Lentiviral globin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentiviral globin gene therapy with reduced-intensity conditioning
Trial: 34981077
Drug: Bamlanivimab 7000
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab 7000 mg and 700 mg
Trial: 34981142
Drug: CC-90002 (anti-CD47
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90002 (anti-CD47 monoclonal antibody) administered in escalating doses of 0.1-4.0 mg/kg
Trial: 34981144
Drug: Deferiprone (DFP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (DFP), single 1500 mg dose
Trial: 34981300
Drug: Hypofractionated stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated stereotactic radiotherapy (HSRT) with doses of either 27.5 or 30 Gy
Trial: 34981464
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) for 16 sessions
Trial: 34983430
Drug: Procalcitonin (PCT)
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin (PCT) with cutoff of 0.5 ng/mL
Trial: 34983430
Drug: PCT for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT for predicting sepsis-3 with cutoff of 0.5 ng/mL
Trial: 34983600
Drug: Early, biomarker-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early, biomarker-guided steroid dosing
Trial: 34983671
Drug: First Phase
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Phase Insulin Response (FPIR) in IvGTT
Trial: 34983751
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation of ≥1.5 g/kg/day in addition to standard nutrition for 7 days or until PICU discharge.
Trial: 34983758
Drug: Cessation programme
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cessation programme with 3-monthly visits
Trial: 34984540
Drug: Sugemalimab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab (1200 mg fixed dose once every 3 weeks)
Trial: 34984540
Drug: Sugemalimab (monotherapy)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Sugemalimab (DB16641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab (monotherapy)
Trial: 34984540
Drug: Sugemalimab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab (in combination with SOC chemotherapy)
Trial: 34987618
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccines (DCV) plus neoadjuvant chemotherapy (NAC)
Trial: 34987618
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) alone
Trial: 34988132
Drug: Oral Water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Water
Trial: 34988480
Drug: Chemoradiation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation treatment for esophageal cancer
Trial: 34988780
Drug: DiffCORE MR
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DiffCORE MR formulations (240 mg) administered in fasted and fed states
Trial: 34988780
Drug: DiffCORE MR-16
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DiffCORE MR-16 h formulation (120-960 mg)
Trial: 34988917
Drug: Treatment intensification
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intensification (addition of new insulin, increase in insulin dosage, increase in insulin injection frequency, addition of non-insulin antihyperglycemic agents)
Trial: 34988917
Drug: Insulin intensification
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin intensification (increase in insulin dose, addition of new insulin, increase in insulin injection frequency)
Trial: 34988917
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in insulin dose
Trial: 34988917
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of new insulin
Trial: 34988917
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in insulin injection frequency
Trial: 34989180
Drug: Felcisetrag 0.2-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felcisetrag 0.2-mg intravenous dose
Trial: 34989180
Drug: Itraconazole 200-mg
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200-mg oral doses
Trial: 34989842
Drug: Radiologic scores
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiologic scores for guiding individualized induction chemotherapy
Trial: 34990408
Drug: Low-dose aerosol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aerosol (LD) AdHu5Ag85A
Trial: 34990408
Drug: High-dose aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aerosol (HD) AdHu5Ag85A
Trial: 34990408
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection of AdHu5Ag85A
Trial: 34990778
Drug: Proton radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton radiation therapy (PRT) at a dose of 54 Gy relative biological effectiveness
Trial: 34990810
Drug: Self-amplifying mRNA
RxNorm normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-amplifying mRNA (SAM) vaccine delivered by lipid nanoparticles (LNPs); two doses administered.
Trial: 34990810
Drug: Self-amplifying mRNA
RxNorm normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-amplifying mRNA (SAM) vaccine; two doses administered.
Trial: 34991141
Drug: BIC/FTC/TAF coformulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC/FTC/TAF coformulated as a single daily pill for 28 days
Trial: 34991511
Drug: Emotion regulation-enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion regulation-enhanced group treatment
Trial: 34991660
Drug: Unmet medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmet medication needs
Trial: 34991660
Drug: Higher proportion
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher proportion of unmet medication needs
Trial: 34991660
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no unmet medication needs)
Trial: 34991688
Drug: Dubbing language
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dubbing language cinema-based therapy
Trial: 34991701
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) and two mobile health (mHealth) components: oral health promotion messages and storytelling videos delivered using WhatsApp messenger
Trial: 34991703
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral montelukast every 24 hours
Trial: 34991937
Drug: PCSK9 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitors (PCSK9-I) therapy
Trial: 34992051
Drug: Average daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average daily steps (Fitbit)
Trial: 34992093
Drug: Andecaliximab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab monotherapy (800 mg IV Q2W)
Trial: 34992093
Drug: Andecaliximab in
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab in combination with nivolumab (800 mg IV Q2W)
Trial: 34992118
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (LDN) 4.5 mg/day
Trial: 34992372
Drug: Vortioxetine 10
RxNorm normalized name: vortioxetine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine 10 mg or 20 mg
Trial: 34992575
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment during on-hours
Trial: 34992575
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment during off-hours
Trial: 34992825
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin
Trial: 34994093
Drug: 225 mg
RxNorm normalized name: tyrosine 225 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg of oral testosterone undecanoate (TLANDO) twice a day for 24 days
Trial: 34994777
Drug: ST266 eye
RxNorm normalized name: ST266
DrugBank: ST266 (DB18614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST266 eye drops, 4 times daily for 28 days
Trial: 34995128
Drug: Early locoregional
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early locoregional therapy (surgery and radiotherapy per standards for nonmetastatic disease)
Trial: 34995128
Drug: Continued systemic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued systemic therapy